Epidemiology of respiratory syncytial virus in Japan: A nationwide claims database analysis
Open Access
- 17 December 2021
- journal article
- research article
- Published by Wiley in Pediatrics International
- Vol. 64 (1) , e14957
Abstract
Background: Respiratory syncytial virus (RSV) is a major cause of hospitalization for bronchiolitis and pneumonia in infancy. In Japan, limited data are publicly available on RSV epidemiology and clinical characteristics among infants. Methods: This retrospective study described RSV incidence, seasonality, patient characteristics, resource use, and clinical outcomes among Japanese children <2 years from January 2017 through December 2018. The RSV cases were identified using the Japanese Medical Data Center database. Results: In the database, 9,711 and 8,509 RSV patients <2 years were identified in 2017 and 2018, respectively. Of these, 25% required hospitalization. Ninety percent of hospitalized patients did not have a known RSV risk factor. Nineteen percent of hospitalized patients experienced dehydration, and 12% had acute respiratory failure. Hospitalization lasted 1 week on average and 7% required some type of mechanical ventilation. The peak of hospitalizations occurred at 2 months. The incidence of RSV hospitalization in children <2 years was 23.2 per 1,000 person‐years, which increased to 35.4 per 1,000 for infants <6 months. This age group accounted for 40% of all RSV‐associated hospitalizations among children <2 years. Conclusions: Roughly one‐fourth of all RSV patients <2 years were hospitalized. Ninety percent of these did not have an underlying risk condition. This underscores that RSV can cause serious disease among all young children. Three to four out of every 100 Japanese children <6 months were hospitalized for RSV, and this age group accounted for ~40% of all RSV‐associated hospitalizations. Novel and broad‐based RSV prevention strategies, especially those targeting young infants, are needed.Keywords
This publication has 25 references indexed in Scilit:
- Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus InfectionPediatrics, 2014
- Three-Year Study of Viral Etiology and Features of Febrile Respiratory Tract Infections in Japanese Pediatric OutpatientsThe Pediatric Infectious Disease Journal, 2014
- Appropriateness of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Moderate-Preterm InfantsJAMA Pediatrics, 2013
- Respiratory Syncytial Virus–Associated Hospitalizations Among Children Less Than 24 Months of AgePediatrics, 2013
- Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high‐risk infants in JapanPediatrics International, 2010
- Distinctive clinical features of human bocavirus in children younger than 2 yearsEuropean Journal of Pediatrics, 2010
- Breastfeeding reduces the severity of respiratory syncytial virus infection among young infants: A multi‐center prospective studyPediatrics International, 2009
- Emerging Genotypes of Human Respiratory Syncytial Virus Subgroup A among Patients in JapanJournal of Clinical Microbiology, 2009
- Severe Respiratory Syncytial Virus Bronchiolitis in Infancy and Asthma and Allergy at Age 13American Journal of Respiratory and Critical Care Medicine, 2005
- Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999The Pediatric Infectious Disease Journal, 2002